{"id":8369,"date":"2014-05-13T00:00:00","date_gmt":"2014-05-12T22:00:00","guid":{"rendered":"https:\/\/idibell.cat\/blog\/2014\/05\/13\/identificats-dos-nous-gens-implicats-en-el-cancer-de-prostata-mes-agressiu-el-cancer-de-prostata-identificar-els-pacients-dalt-risc-dos-nous-gens-en-el-punt-de-mira\/"},"modified":"2021-11-15T17:57:24","modified_gmt":"2021-11-15T16:57:24","slug":"identificats-dos-nous-gens-implicats-en-el-cancer-de-prostata-mes-agressiu-el-cancer-de-prostata-identificar-els-pacients-dalt-risc-dos-nous-gens-en-el-punt-de-mira","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2014\/05\/identificats-dos-nous-gens-implicats-en-el-cancer-de-prostata-mes-agressiu-el-cancer-de-prostata-identificar-els-pacients-dalt-risc-dos-nous-gens-en-el-punt-de-mira\/","title":{"rendered":"Identificats dos nous gens implicats en el c\u00e0ncer de pr\u00f2stata m\u00e9s agressiu"},"content":{"rendered":"<p>Un estudi de la Universitat de Columbia de Nova York, en col\u00b7laboraci\u00f3 amb l\u2019Institut Catal\u00e0 d\u2019Oncologia-Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (ICO-IDIBELL), ha identificat dos nous gens que condueixen a formes m\u00e9s agressives de c\u00e0ncer de pr\u00f2stata. El treball, realitzat per \u00c0lvaro Aytes sota la direcci\u00f3 de Cory Abate-Shen, directora del Herbert Irving Comprehensive Cancer Center de la Universitat de Columbia, s\u2019ha publicat en el darrer n\u00famero de <em>Cancer Cell<\/em>.<\/p>\n<p>El c\u00e0ncer de pr\u00f2stata \u00e9s el m\u00e9s freq\u00fcent en els homes (suposa el 20% de tots els tumors masculins). La incid\u00e8ncia \u00e9s d\u2019uns 60 nous casos per 100.000 habitants i any. A Catalunya es donen prop de 5.000 casos nous l\u2019any i, a tota Espanya, uns 25.000. \u00c9s un tumor fortament associat a edats avan\u00e7ades, i la majoria de casos es diagnostiquen entre els 70 i els 80 anys. El progressiu envelliment de la poblaci\u00f3 ha fet que sigui un dels tumors que m\u00e9s ha augmentat en les darreres d\u00e8cades. La superviv\u00e8ncia \u00e9s for\u00e7a elevada: segons dades del Pla Director d\u2019Oncologia, el 84% dels pacients segueixen vius cinc anys despr\u00e9s del diagn\u00f2stic.<\/p>\n<p>En una proporci\u00f3 important de pacients el tumor de pr\u00f2stata t\u00e9 un comportament poc agressiu, que no compromet la salut ni la qualitat de vida de l\u2019afectat. A m\u00e9s, en ser un tumor que sol apar\u00e8ixer en edats avan\u00e7ades, moltes vegades la persona mor amb el tumor per\u00f2 no a conseq\u00fc\u00e8ncia d\u2019aquest. Aquesta circumst\u00e0ncia fa necessari el desenvolupament d\u2019eines que permetin predir quins tumors de pr\u00f2stata seran cl\u00ednicament rellevants i potencialment letals. Aix\u00f2 obre la porta a personalitzar els tractaments i evitar certes ter\u00e0pies i, per tant, els efectes secundaris que comporten, als pacients que no ho necessiten, reduint, a m\u00e9s, els costos sanitaris.<\/p>\n<p>L\u2019estudi que publica <em>Cancer Cell<\/em> ha identificat dos gens, el FOXM1 i el CENPF, que si s\u2019activen de manera an\u00f2mala alhora, condueixen a formes m\u00e9s agressives i potencialment letals del c\u00e0ncer de pr\u00f2stata. Una de les novetats de l\u2019estudi \u00e9s que s\u2019han emprat algoritmes inform\u00e0tics per generar xarxes de les interaccions entre les mol\u00e8cules que es generen espec\u00edficament en el c\u00e0ncer de pr\u00f2stata.<\/p>\n<p>Actualment s\u2019han posat en marxa estudis precl\u00ednics per determinar quins tractaments o combinacions de f\u00e0rmacs s\u00f3n m\u00e9s efica\u00e7os per a combatre activaci\u00f3 an\u00f2mala dels gens FOXM1 i CENPF. Aix\u00ed mateix, en un futur proper, identificar la pres\u00e8ncia o no d\u2019aquests biomarcadors en un pacient concret permetr\u00e0 oferir un tractament individualitzat, m\u00e9s efica\u00e7 i amb menys efectes secundaris. La Comissi\u00f3 Europea, a trav\u00e9s de les accions Marie Curie del 7\u00e8 Programa Marc, ha estat la font de finan\u00e7ament d\u2019\u00c1lvaro Aytes per al desenvolupament del projecte, en col\u00b7laboraci\u00f3 entre els grups de Biologia de Sistemes i Quimioresist\u00e8ncia de l\u2019ICO-IDIBELL i la Universitat de Columbia, a Nova York<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Un estudi de la Universitat de Columbia de Nova York, en col\u00b7laboraci\u00f3 amb l\u2019Institut Catal\u00e0 d\u2019Oncologia-Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (ICO-IDIBELL), ha identificat dos nous gens que condueixen a formes m\u00e9s agressives de c\u00e0ncer de pr\u00f2stata. El treball, realitzat per \u00c0lvaro Aytes sota la direcci\u00f3 de Cory Abate-Shen, directora del Herbert Irving Comprehensive Cancer Center [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":11013,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[1,332,395,447],"tags":[],"class_list":["post-8369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sin-categorizar","category-cancer","category-mecanismes-de-resistencia-i-progressio-en-el-cancer-de-prostata","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell"],"publishpress_future_action":{"enabled":false,"date":"2024-12-30 16:43:59","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=8369"}],"version-history":[{"count":4,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8369\/revisions"}],"predecessor-version":[{"id":19661,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/8369\/revisions\/19661"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/11013"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=8369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=8369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=8369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}